Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shijiazhuang Polee Pharmaceutical is a Chinese pharmaceutical manufacturer focused primarily on commercial small-molecule active pharmaceutical ingredients, pharmaceutical excipients, intermediates, and increasingly finished-dose products. The company is best known for cimetidine and metformin hydrochloride, and it has described itself as a major domestic cimetidine producer with GMP-compliant manufacturing. Publicly available Chinese-language sources indicate the company was founded in 2006 and operates production and R&D activities in Zhao County, Shijiazhuang, Hebei Province. More recent drug-approval listings suggest it has expanded from API manufacturing into formulations, including empagliflozin tablets and metformin hydrochloride extended-release tablets. Overall, it appears to be a commercial-stage, privately held generic pharma and manufacturing company rather than a venture-backed discovery biotech.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shijiazhuang Polee Pharmaceutical.